IP Library Granted Patent US 8,691,208
Granted Patent B2
US 8,691,208 · App. 13/071,445 · Granted Apr 8, 2014

Compositions and methods for treating hypophosphatasia

Inventors: Shunji Tomatsu (Saint Louis, MO); William Sly (Saint Louis, MO); Jeffrey Grubb (Saint Louis, MO); Tatsuo Nishioka (Kanazawa, JP); Ken-ichi Miyamoto (Kanazawa, JP); Seiji Yamaguchi (Izumo, JP)
Assignees: Saint Louis University; Shimane University; Kanazawa University
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,691,208
App. No.
13/071,445
Granted
Apr 8, 2014
Kind
B2
Abstract

The present invention provides compositions and methods for use in enzyme replacement therapy. The inventors disclose a method of producing membrane bound enzymes in an active soluble form by eliminating the glycosylphosphatidylinositol (GPI) membrane anchor. In particular the inventors disclose a soluble active form of the membrane bound enzyme TNSALP which they produced by deleting the GPI anchor single peptide sequence. They have further shown that this composition is useful for treatment of hypophosphatasia. The inventors also disclose oligo acid amino acid variants thereof which specifically target bone tissue.

Claims (11)

1. A method for treating hypophosphatasia in a patient comprising administering to said patient an effective amount of a composition comprising a nucleic acid molecule encoding a physiologically active, anchorless, untagged alkaline phosphatase, wherein said alkaline phosphatase is expressed from said nucleic acid molecule, thereby treating said hypophosphatasia in said patient.

2. The method of claim 1 , wherein said alkaline phosphatase is recombinant human tissue non-specific alkaline phosphatase (rhTNSALP).

3. The method of claim 1 , wherein the amino acid sequence of said alkaline phosphatase encoded by said nucleic acid molecule consists of the sequence set forth in amino acid residues 1-505 of SEQ ID NO:1.

4. The method of claim 1 , wherein said composition is administered to said patient by injection.

5. The method of claim 1 , wherein said composition is formulated in an injectable aqueous solution.

6. The method of claim 1 , wherein the life span of said patient is increased.

7. The method of claim 1 , wherein bone mineralization of said patient is increased.

8. The method of claim 1 , wherein body weight of said patient is increased.

9. The method of claim 1 , wherein epileptic seizure is decreased in said patient.

10. The method of claim 1 , wherein said nucleic acid molecule of said composition is in an isolated host cell, and wherein said host cell expresses and secretes said physiologically active, anchorless, untagged alkaline phosphatase.

11. The method of claim 1 , wherein said patient is a human.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 13, 2014
From: SAINT LOUIS UNIVERSITY
To: SAINT LOUIS UNIVERSITY; SHIMANE UNIVERSITY; KANAZAWA UNIVERSITY
Reel/Frame 032214/0107 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 14, 2012
From: TOMATSU, SHUNJI; NISHIOKA, TATSUO; GRUBB, JEFFREY H.; SLY, WILLIAM S.; YAMAGUCHI, SEIJI; MIYAMOTO, KEN-ICHI
To: SAINT LOUIS UNIVERSITY
Reel/Frame 028378/0854 →
Continuity (4)
Division 12405920 · Mar 17, 2009
Division 11484870 · Jul 11, 2006
Provisional Application 60725563 · Oct 11, 2005
Related Publication 20110250187A1 · Oct 13, 2011